{
  "pmcid": "10638529",
  "abstract": "300-word version:\n\nTitle: Randomised Controlled Trial of Autofluorescence in Thyroidectomy\n\nBackground: This multicentre randomised controlled trial assessed the efficacy of Fluobeam速 LX in visualizing parathyroid glands during total thyroidectomy to mitigate postoperative hypoparathyroidism.\n\nMethods: Conducted across four European centres, the trial included patients over 18 years scheduled for total thyroidectomy. Participants were randomised 1:1 to either the intervention group using Fluobeam速 LX or a control group without it. The primary outcome was the rate of low parathyroid hormone (PTH) levels on the first postoperative day. Randomisation was executed via the Eurocrine速 platform, with allocation concealed from patients, ensuring a single-blinded design. The sample size calculation aimed to detect a reduction in low PTH rates from 15% to 5%, requiring 280 patients.\n\nResults: From January 2021 to August 2022, 535 patients were randomised, and 486 were analysed (246 intervention, 240 control). The intervention group had a 26.0% rate of low PTH levels compared to 32.1% in the control group (RR 0.81, 95% CI 0.61 to 1.07; p = 0.141). In a subgroup undergoing central lymph node dissection, the rates were 18.3% and 33.7%, respectively (RR 0.54, 95% CI 0.31 to 0.93; p = 0.021). No specific harm related to Fluobeam速 LX was reported.\n\nInterpretation: While autofluorescence did not significantly reduce low PTH rates in the overall cohort, it was beneficial in a subgroup undergoing central lymph node dissection. The technique facilitated better identification and preservation of parathyroid glands. Trial registration: NCT04509011. Funding: Not specified.",
  "word_count": 243
}